Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Trading Down 4.5 %

Shares of VNDA stock traded down $0.21 on Friday, reaching $4.49. The company’s stock had a trading volume of 973,352 shares, compared to its average volume of 594,076. The company has a market capitalization of $261.81 million, a price-to-earnings ratio of -16.02 and a beta of 0.74. The stock’s fifty day simple moving average is $4.63 and its 200-day simple moving average is $4.87. Vanda Pharmaceuticals has a 1 year low of $3.71 and a 1 year high of $6.75.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on VNDA shares. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 4th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.